ES2228527T5 - Derivados del ácido propanoico que inhiben la unión de las integrinas a sus receptores - Google Patents

Derivados del ácido propanoico que inhiben la unión de las integrinas a sus receptores Download PDF

Info

Publication number: ES2228527T5
Authority: ES; Spain
Prior art keywords: alkyl; amino; compound; group; alkylamino
Prior art date: 1999-05-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES00930450T

Other languages

English (en)

Spanish (es)

Other versions

ES2228527T3 (es

Inventor

Ronald J. Biediger

George W. Holland

Jamal M. Kassir

Wen Li

Robert V. Market

Ian L. Scott

Chengde Wu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Encysive Pharmaceuticals Inc

Original Assignee

Encysive Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-07

Filing date

2000-05-05

Publication date

2013-05-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26830910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2228527(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-05 Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc

2005-04-16 Application granted granted Critical

2005-04-16 Publication of ES2228527T3 publication Critical patent/ES2228527T3/es

2013-05-23 Publication of ES2228527T5 publication Critical patent/ES2228527T5/es

2020-05-05 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES00930450T 1999-05-07 2000-05-05 Derivados del ácido propanoico que inhiben la unión de las integrinas a sus receptores Expired - Lifetime ES2228527T5 (es)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US13296799P	1999-05-07	1999-05-07
US132967P		1999-05-07
US17044199P	1999-12-10	1999-12-10
US170441P		1999-12-10
PCT/US2000/012464 WO2000068188A1 (fr)	1999-05-07	2000-05-05	Derives de l'acide propanoique inhibant la liaison des integrines a leurs recepteurs

Publications (2)

Publication Number	Publication Date
ES2228527T3 ES2228527T3 (es)	2005-04-16
ES2228527T5 true ES2228527T5 (es)	2013-05-23

Family

ID=26830910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES00930450T Expired - Lifetime ES2228527T5 (es)	1999-05-07	2000-05-05	Derivados del ácido propanoico que inhiben la unión de las integrinas a sus receptores

Country Status (23)

Country	Link
EP (1)	EP1189881B2 (fr)
JP (2)	JP4841729B2 (fr)
KR (1)	KR100767199B1 (fr)
CN (1)	CN100360499C (fr)
AT (1)	ATE277923T1 (fr)
AU (1)	AU4826900A (fr)
BR (1)	BR0010349B1 (fr)
CA (1)	CA2373180C (fr)
CZ (1)	CZ304225B6 (fr)
DE (1)	DE60014369T3 (fr)
ES (1)	ES2228527T5 (fr)
HK (1)	HK1044533A1 (fr)
HU (1)	HU229155B1 (fr)
IL (2)	IL146312A0 (fr)
MX (1)	MXPA01011341A (fr)
NO (1)	NO329899B1 (fr)
NZ (1)	NZ515249A (fr)
RO (1)	RO121640B1 (fr)
RU (1)	RU2255933C9 (fr)
SI (1)	SI20876B (fr)
SK (1)	SK288186B6 (fr)
TR (1)	TR200103427T2 (fr)
WO (1)	WO2000068188A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6972296B2 (en) *	1999-05-07	2005-12-06	Encysive Pharmaceuticals Inc.	Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) *	1999-05-07	2004-04-20	Texas Biotechnology Corporation	Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (es)	1999-12-08	2003-02-26	Vertex Pharma	Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
AR030817A1 (es) *	2000-10-02	2003-09-03	Novartis Ag	Derivados de diazacicloalcanodiona
FR2834212B1 (fr) *	2001-12-27	2004-07-09	Besins Int Belgique	Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US7553852B2 (en)	2002-06-28	2009-06-30	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
PL374971A1 (en)	2002-08-09	2005-11-14	Transtech Pharma, Inc.	Aryl and heteroaryl compounds and methods to modulate coagulation
AU2003303345A1 (en)	2002-12-20	2004-07-22	Vertex Pharmaceuticals, Inc.	4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (es)	2003-05-27	2005-04-19	Vertex Pharma	Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
WO2005014532A1 (fr)	2003-08-08	2005-02-17	Transtech Pharma, Inc.	Composes aryle et heteroaryle, compositions et procedes associes
CN1832920A (zh)	2003-08-08	2006-09-13	特兰斯泰克制药公司	芳基和杂芳基化合物,组合物及其使用方法
US7208601B2 (en)	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
WO2006053342A2 (fr) *	2004-11-12	2006-05-18	Osi Pharmaceuticals, Inc.	Antagonistes de l'integrine utiles en tant qu'agents anticancereux
PT1928454E (pt)	2005-05-10	2014-12-04	Intermune Inc	Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress
WO2007008994A2 (fr)	2005-07-11	2007-01-18	Wyeth	Inhibiteurs de glutamate aggrecanase
KR20080058436A (ko)	2005-10-13	2008-06-25	와이어쓰	글루탐산 유도체의 제조 방법
US8304413B2 (en)	2008-06-03	2012-11-06	Intermune, Inc.	Compounds and methods for treating inflammatory and fibrotic disorders
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
KR102373700B1 (ko)	2014-04-02	2022-03-11	인터뮨, 인크.	항섬유성 피리디논
US10875875B2 (en) *	2017-04-26	2020-12-29	Aviara Pharmaceuticals, Inc.	Propionic acid derivatives and methods of use thereof
EP3773573A4 (fr)	2018-04-12	2022-04-06	Morphic Therapeutic, Inc.	Antagonistes de l'intégrine humaine (alpha4) (beta7)
RS66976B1 (sr) *	2019-10-16	2025-07-31	Morphic Therapeutic Inc	Inhibiranje ljudskog integrina alfa4beta7
WO2023134698A1 (fr) *	2022-01-11	2023-07-20	深圳信立泰药业股份有限公司	Composé pyridazine-1(6h)-6-oxo, son procédé de préparation et son application
CN121127462A (zh) *	2023-05-17	2025-12-12	西藏海思科制药有限公司	一种羧基衍生物及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5874424A (en) *	1995-12-20	1999-02-23	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
GR851819B (fr) *	1984-08-17	1985-11-26	Wyeth John & Brother Ltd
WO1992019595A1 (fr) *	1991-05-07	1992-11-12	Merck & Co., Inc.	Antagonistes de recepteur de fibrinogene
US5847135A (en) *	1994-06-17	1998-12-08	Vertex Pharmaceuticals, Incorporated	Inhibitors of interleukin-1β converting enzyme
EP0761680A3 (fr) *	1995-09-12	1999-05-06	Ono Pharmaceutical Co., Ltd.	Composés de tétrazole ayant une activité inhibante d'enzyme convertissant l'Interleukine-1bêta
WO1998004247A1 (fr) *	1996-07-25	1998-02-05	Biogen, Inc.	Inhibiteurs d'adhesion cellulaire
CA2263999A1 (fr) *	1996-08-29	1998-03-05	Merck & Co., Inc.	Antagonistes de l'integrine
WO1998016502A1 (fr) *	1996-10-11	1998-04-23	Warner-Lambert Company	INHIBITEURS A BASE D'ESTER D'ASPARTATE DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
DE19647380A1 (de) *	1996-11-15	1998-05-20	Hoechst Ag	5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
AR016751A1 (es) *	1996-11-22	2001-08-01	Athena Neurosciences Inc	Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
PL336589A1 (en) *	1997-05-02	2000-07-03	Akzo Nobel Nv	Serinic protease inhibitors
DE19741235A1 (de) *	1997-09-18	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6331640B1 (en) *	1998-10-13	2001-12-18	Hoffmann-La Roche Inc.	Diaminopropionic acid derivatives
WO2000061631A1 (fr) *	1999-04-12	2000-10-19	Astrazeneca Ab	Antagonistes de pentapeptides modifies du recepteur de la clairance des peptides natriuretiques auriculaires

2000
- 2000-05-05 IL IL14631200A patent/IL146312A0/xx unknown
- 2000-05-05 RO ROA200101209A patent/RO121640B1/ro unknown
- 2000-05-05 KR KR1020017014179A patent/KR100767199B1/ko not_active Expired - Fee Related
- 2000-05-05 RU RU2001133341/04A patent/RU2255933C9/ru not_active IP Right Cessation
- 2000-05-05 AT AT00930450T patent/ATE277923T1/de not_active IP Right Cessation
- 2000-05-05 SK SK1609-2001A patent/SK288186B6/sk not_active IP Right Cessation
- 2000-05-05 TR TR2001/03427T patent/TR200103427T2/xx unknown
- 2000-05-05 HK HK02106258.2A patent/HK1044533A1/zh unknown
- 2000-05-05 EP EP00930450A patent/EP1189881B2/fr not_active Expired - Lifetime
- 2000-05-05 BR BRPI0010349-7A patent/BR0010349B1/pt not_active IP Right Cessation
- 2000-05-05 MX MXPA01011341A patent/MXPA01011341A/es active IP Right Grant
- 2000-05-05 CZ CZ2001-3983A patent/CZ304225B6/cs not_active IP Right Cessation
- 2000-05-05 SI SI200020020A patent/SI20876B/sl not_active IP Right Cessation
- 2000-05-05 HU HU0202184A patent/HU229155B1/hu not_active IP Right Cessation
- 2000-05-05 JP JP2000617169A patent/JP4841729B2/ja not_active Expired - Fee Related
- 2000-05-05 ES ES00930450T patent/ES2228527T5/es not_active Expired - Lifetime
- 2000-05-05 AU AU48269/00A patent/AU4826900A/en not_active Abandoned
- 2000-05-05 NZ NZ515249A patent/NZ515249A/en not_active IP Right Cessation
- 2000-05-05 CA CA002373180A patent/CA2373180C/fr not_active Expired - Fee Related
- 2000-05-05 DE DE60014369T patent/DE60014369T3/de not_active Expired - Lifetime
- 2000-05-05 WO PCT/US2000/012464 patent/WO2000068188A1/fr not_active Ceased
- 2000-05-05 CN CNB00809957XA patent/CN100360499C/zh not_active Expired - Fee Related
2001
- 2001-11-01 IL IL146312A patent/IL146312A/en not_active IP Right Cessation
- 2001-11-06 NO NO20015419A patent/NO329899B1/no not_active IP Right Cessation
2011
- 2011-07-14 JP JP2011155493A patent/JP5468578B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1189881B1 (fr)	2004-09-29
ATE277923T1 (de)	2004-10-15
SI20876B (sl)	2009-08-31
BR0010349C1 (pt)	2003-11-04
SK16092001A3 (sk)	2002-04-04
CZ304225B6 (cs)	2014-01-15
PL354957A1 (en)	2004-03-22
TR200103427T2 (tr)	2002-10-21
KR100767199B1 (ko)	2007-10-17
EP1189881A4 (fr)	2002-11-27
NO20015419L (no)	2001-12-20
WO2000068188A1 (fr)	2000-11-16
EP1189881A1 (fr)	2002-03-27
CN100360499C (zh)	2008-01-09
AU4826900A (en)	2000-11-21
DE60014369D1 (de)	2004-11-04
JP5468578B2 (ja)	2014-04-09
DE60014369T3 (de)	2013-06-27
IL146312A0 (en)	2002-07-25
NO20015419D0 (no)	2001-11-06
WO2000068188A9 (fr)	2002-08-29
HUP0202184A3 (en)	2003-03-28
CZ20013983A3 (cs)	2002-04-17
JP2012006932A (ja)	2012-01-12
CN1370143A (zh)	2002-09-18
JP4841729B2 (ja)	2011-12-21
BR0010349B1 (pt)	2011-10-04
IL146312A (en)	2010-12-30
MXPA01011341A (es)	2002-06-21
RO121640B1 (ro)	2008-01-30
DE60014369T2 (de)	2005-11-24
SK288186B6 (sk)	2014-05-06
CA2373180C (fr)	2009-12-15
RU2255933C9 (ru)	2005-11-20
KR20020009608A (ko)	2002-02-01
NZ515249A (en)	2004-07-30
SI20876A (sl)	2002-10-31
HU229155B1 (en)	2013-09-30
NO329899B1 (no)	2011-01-24
BR0010349A (pt)	2003-07-08
HK1044533A1 (zh)	2002-10-25
RU2255933C2 (ru)	2005-07-10
CA2373180A1 (fr)	2000-11-16
EP1189881B2 (fr)	2013-01-23
ES2228527T3 (es)	2005-04-16
JP2002544187A (ja)	2002-12-24
HUP0202184A2 (hu)	2002-12-28

Publication	Publication Date	Title
ES2228527T5 (es)	2013-05-23	Derivados del ácido propanoico que inhiben la unión de las integrinas a sus receptores
US6194448B1 (en)	2001-02-27	N, N-disubstituted amides that inhibit the binding of integrins to their receptors
ES2296625T3 (es)	2008-05-01	Derivados del acido carboxilico que inhiben el enlace de las integrinas con sus receptores.
ES2321059T3 (es)	2009-06-02	Derivados de acido propanoico que inhiben la union de integrinas a sus receptores.
AU759154B2 (en)	2003-04-10	Compounds that inhibit the binding of integrins to their receptors
AU763115B2 (en)	2003-07-10	N,N-disubstituted amides that inhibit the binding of integrins to their receptors
CA2361285C (fr)	2009-10-27	Derives de l'acide propanoique qui inhibent la liaison d'integrines a leurs recepteurs
ZA200108771B (en)	2003-01-24	Propanoic acid derivatives that inhibit the binding of integrins to their receptors.
HK1045805B (en)	2008-12-24	Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
MXPA00010098A (es)	2001-09-07	Compuestos que inhiben la union de integrinas con sus receptores